3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Genitourinary
1
Endocrine
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Zoledronic Acid
15
enzalutamide
10
Leuprolide
9
Goserelin
8
bicalutamide
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
6
Triptorelin Pamoate
6
Prednisone
6
Nivolumab
6
Abiraterone Acetate
6
luprolide acetate gel depot
5
Sunitinib
5
Magnetic Resonance Spectroscopy
5
Everolimus
5
Dutasteride
5
Specimen Handling
4
Sodium Chloride
4
Propofol
4
Prednisolone
4
Androgen Antagonists
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
pazopanib
3
fluciclovine F-18
3
darolutamide
3
cabazitaxel
3
Trimethoprim, Sulfamethoxazole Drug Combination
3
Rocuronium
3
Mitomycin
3
Midazolam
3
Flutamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
gadoterate meglumine
×
Genitourinary
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled